Psoriasis News and Research

Latest Psoriasis News and Research

Psoriasis lesions loaded with newly discovered immune cell

A new study of psoriasis patients shows that a recently discovered immune cell, called Th17, appears to be a key player in the disease and occurs in far higher concentrations in their skin than occurs in skin of healthy individuals.

22 Feb 2008

Enbrel shown to significantly reduced levels of C-reactive protein

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group.

5 Feb 2008

Arthritis drug Etanercept clears up symptoms of psoriasis

New research from the United States has found that a drug commonly used to treat arthritis significantly reduces the symptoms of psoriasis in children.

20 Jan 2008

New drug lets kids feel good in their skin

Maria Anichini, a 20-year-old junior at Columbia College, zipped up a fetching black lace cocktail dress with spaghetti straps to go out with friends the other night.

17 Jan 2008

Severe psoriasis can cut short life

According to a new study having some forms of psoriasis can shorten a person's lifespan.

19 Dec 2007

Severe psoriasis associated with increased risk of death

Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

18 Dec 2007

Isotechnika granted Norwegian patent for lead immunosuppressive drug

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

27 Nov 2007

Newly completed genome sequence may provide new treatment options for dandruff

Scientists from P&G Beauty announced that they successfully sequenced the complete genome for Malassezia globosa (M. globosa) , a naturally occurring fungus responsible for the onset of dandruff and other skin conditions in humans.

6 Nov 2007

Smoking linked to enduring risk of psoriasis

According to new research smokers have a higher risk of developing the skin condition psoriasis.

29 Oct 2007

Discovery of two genes linked to a disabling form of arthritis called ankylosing spondylitis

An international team of researchers led by a Fred Hutchinson Cancer Research Center geneticist has discovered two genes linked to a disabling form of arthritis called ankylosing spondylitis, a painful and progressive disease in which some or all of the spine's vertebrae fuse together.

22 Oct 2007

Lilly and MacroGenics to develop and commercialize teplizumab

Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.

19 Oct 2007

Myositis featured on Discovery Channel

LaShan Davis, featured this week on The Discovery Channel's “Mystery Diagnosis” spent three 10-hour days filming the segment and reliving the terrifying time she spent waiting for her “mystery disease” to be diagnosed.

17 Oct 2007

Promising trial results show biologic therapy ustekinumab significantly improved psoriasis

The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).

4 Oct 2007

Indian bug is the ancestor of Crohn's disease pathogen

An Indian team of researchers led by Seyed E. Hasnain of the Institute of Life Sciences (ILS), University of Hyderabad, India has found that a seemingly unknown mycobacterial organism Mycobacterium indicus pranii (MIP) could be the earliest ancestor of the 'generalist' branch of mycobacterial pathogens.

3 Oct 2007

LL37 peptide provides a new potential target for autoimmune disease

A human peptide that acts as a natural antibiotic against invading microbes can also bind to the body's own DNA and trigger an immune response in the absence of an infection, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in an early online publication in Nature.

17 Sep 2007

Cell that triggers symptoms in allergy attacks can also limit damage

A blood cell known as a troublemaker for triggering the itch and inflammation in allergy attacks, the mast cell, can also calm down the flare-ups, researchers from Stanford University School of Medicine have found.

3 Sep 2007

Skin-healing pseudoceramides

Researchers report in the September 2007 issue of the Journal of Lipid Research that they have made synthetic lipids called pseudoceramides that are involved in skin cell growth and could be used in treating skin diseases in which skin cells grow abnormally.

29 Aug 2007

Green tea may help treat psoriasis

Green tea which is already recommended for its cancer-fighting properties, also appears to be a promising new treatment for skin disorders such as psoriasis, lupus-induced lesions and dandruff.

12 Aug 2007

Green tea holds promise for psoriasis and dandruff

Green tea could hold promise as a new treatment for skin disorders such as psoriasis and dandruff, Medical College of Georgia researchers say.

7 Aug 2007

Efalizumab effective in treatment of heavy psoriasis

A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers at Mount Sinai School of Medicine announced today.

3 Aug 2007